Curagen melanoma trial progresses to second stage
US drug developer CuraGen has met the criteria to proceed to the next stage of its Phase II trial of CR011-vcMMAE, a treatment for melanoma.
The ongoing open-label, multicenter, study is evaluating the antibody-drug conjugate in the treatment of patients with unreselectable Stage III or Stage IV melanoma, utilizing the Simon 2-Stage design. The candidate has met the efficacy criteria for the first stage, with one of the six subjects expressing a comfirmed objective response.
The trial will now advance to a second stage, expanding to include 32 patients. Results of an earlier, Phase I trial were reported at the American Society of Clinical Oncology in Chicago earlier this month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze